HRT Financial’s Immunome IMNM Stock Holding History

HRT Financial’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$776K	Buy	+35,500	New	+$790K	﹤0.01%	2213

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

HRT Financial's IMNM Position: Q2 2024 in Review

HRT Financial sold out of Immunome (IMNM) in Q2 2024, closing a stake of 69,305 shares — an estimated $1.71M sold.

HRT Financial first reported a position in IMNM in Q1 2024 and held it in 1 quarter. The position peaked at $1.71M in Q1 2024. 113 funds tracked by Wall St. Rank hold IMNM as of Q2 2024.

HRT Financial reported no remaining Immunome position as of Q2 2024 after selling out during the quarter.
HRT Financial sold 69,305 Immunome shares in Q2 2024, an estimated $1.71M.
HRT Financial first reported a position in Immunome in Q1 2024 and held it in 1 quarter.
HRT Financial's Immunome position peaked at $1.71M in Q1 2024.
113 funds tracked by Wall St. Rank held Immunome as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.